Medical Weight Loss Center
Medical Weight Loss Center · 250 Pierce Street · Kingston, PA 18704
5.0· 3 Google reviews
Listing updated October 2, 2026
No current plans confirmed — RetaMaps has not yet confirmed this practice's intentions regarding retatrutide. Inclusion on RetaMaps does not mean the provider offers or will offer retatrutide.
Care described on the practice's website
- Medically supervised weight loss
About this practice
Medical Weight Loss Center is a weight-loss practice in Kingston, Pennsylvania. Per its website, the center believes body weight, eating habits and lifestyle all shape a person's weight-loss journey, recommends programs it thinks patients can stick with, and starts with a comprehensive intake consultation covering a blood test, measurements, a weigh-in and a physical exam. It holds a 5.0-star Google rating across 3 reviews, the first from 2016 and none in the past year, with one review mentioning the staff and one mentioning results.
Services & access
| Advertises semaglutide today | Not listed |
| Advertises tirzepatide today | Not listed |
| Telehealth visits | Not listed |
| Cash pay accepted | — |
| Accepts insurance — per practice website | Yes |
| Accepting new patients — per practice website | Yes |
"Not listed" means we didn't find this stated on the practice's public pages — it doesn't mean no. — means unknown. Medication rows describe currently FDA-approved GLP-1 medications the practice advertises today, not retatrutide. Confirm details directly with the practice.
Review activity
Counts computed by RetaMaps from public Google reviews; most recent review 2019-08-11. Read the reviews themselves on the practice's Google listing.
What patients say
Rated ★5.0 across 3 Google reviews. Of the 3 reviews we analyzed, 3 (100%) are positive (4–5★) and 0 (0%) are negative (1–2★).
Most recent Google reviews
Alice R.★★★★★2019-08-11I lost 114 lbs and the staff is very helpful and really care.
Analysis by RetaMaps of reviews on this practice's public Google Business listing; review themes are detected automatically and reviews reflect their authors' opinions. See all reviews on Google.
Retatrutide is Eli Lilly's investigational once-weekly triple agonist (GIP, GLP-1 and glucagon receptors). Five Phase 3 trials have reported positive results, and Lilly plans to submit it to the FDA in Q1 2027. It is not FDA-approved, has no brand name or price, and cannot be prescribed outside clinical trials or Lilly's physician-requested expanded access program. Products sold online as "research" or compounded retatrutide are not legitimate retatrutide.
- Development
- Phase 3 complete
- FDA status
- Submission planned — Q1 2027 (Lilly guidance)
- Availability
- Not commercially available
- Access routes
- Clinical trials, or Lilly's expanded access program (physician must apply)
Next milestone: TRIUMPH-5 head-to-head vs tirzepatide results (Expected ~Dec 2026)
Sources: Lilly — What to know about retatrutide · Lilly — TRIUMPH-2/TRIUMPH-3 results · BioPharma Dive — FDA submission plans · STAT — Lilly expanded access (Aug 3, 2026) · FDA — Concerns with unapproved GLP-1 drugs